Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The calcineurin inhibitor drugs including cyclosporin and tacrolimus are well-known as nephrotoxicity. However, these drugs are essential for kidney transplant especially in high immunological risks. To date, however, there is an alternative regimen by using of everolimus-based which showing less toxicity than tacrolimus-based regimen by its mechanisms. Of note, this study aims to evaluate the toxicity by using microRNA profiles detection between everolimus-based and tacrolimus-based immunosuppressive regimen in kidney transplantation.
The author aims to evaluate the effects of two regimens (everolimus-based versus tacrolimus-based) in kidney transplantation recipients. Both of regimens are prescribed only in recipents who have low immunologicla risks. After informed consent, all eligible recipients will be collected blood and urine sample for microRNA profile testing during study periods.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Everolimus | Experimental | everolimus dosing to tough level 6-10 ng/ml |
|
| Tacrolimus | Experimental | Tacrolimus dosing to target tough level 5-10 ng/ml |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Everolimus | Drug | Everolimus dosing to target tough level 6-10 mg/ml |
| |
| Measure | Description | Time Frame |
|---|---|---|
| microRNA profiles | microRNA profiles including rejection and nephrotoxicity markers | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Allograft tissue pathology | Pathology studies including rejection, interstitial fibrosis and tubular atrophy | At year 2 and 5 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wiwat Chancharoenthana, MD, MSc. | Contact | 6622564251 | 101 | wiwatmd@hotmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Wiwat Chancharoenthana, MD, Msc. | Chulalongkorn University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chulalongkorn University | Recruiting | Bangkok | 10330 | Thailand |
Not provided
| ID | Term |
|---|---|
| D000068338 | Everolimus |
| D016559 | Tacrolimus |
| ID | Term |
|---|---|
| D020123 | Sirolimus |
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tacrolimus |
| Drug |
Tacrolimus dosing to target tough level 5-10 ng/ml |
|